炎症诱导的糖酵解转换通过STAT1糖基化控制间充质干细胞的抑制功能
研究探讨炎症刺激下间充质干细胞(MSC)获得免疫抑制功能(即MSC许可)的代谢调控机制。发现炎症许可导致糖酵解增强和脂肪酸氧化增加,但仅干扰糖酵解可影响IDO上调并削弱T细胞抑制能力;JAK/STAT1通路调控糖酵解和IDO,且STAT1的O-GlcNAc糖基化通过增加其稳定性维持下游效应。该通路可能成为增强MSC免疫调节效力的干预靶点。
要点
- 炎症许可使MSC糖酵解增强和脂肪酸氧化增加,仅糖酵解影响IDO和T细胞抑制。
- JAK/STAT1通路调控糖酵解和IDO,STAT1糖基化与葡萄糖周转增强相关。
- 抑制O-GlcNAc转移酶可消除STAT1活性和IDO上调。
核心结论
- 炎症诱导的MSC许可通过增强糖酵解和STAT1 O-GlcNAc糖基化上调IDO,从而控制MSC对T细胞的抑制功能。
研究设计与样本
- 原文未报告研究设计与样本。
主要发现
- 炎症MSC许可导致代谢转变,包括糖酵解增强和脂肪酸氧化增加。
- 仅干扰糖酵解影响IDO上调并阻碍T细胞抑制。
- JAK/STAT1通路调控糖酵解和IDO,葡萄糖周转增强与STAT1糖基化丰富相关。
- 抑制O-GlcNAc转移酶消除STAT1活性及IDO上调。
- STAT1 O-GlcNAc糖基化可能增加其抗降解稳定性,从而维持下游效应。
关键数值与推荐
- 原文未报告关键数值与推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mesenchymal stem cells (MSCs) represent key contributors to tissue homeostasis and promising therapeutics for hyperinflammatory conditions including graft-versus-host disease. Their immunomodulatory effects are controlled by microenvironmental signals. The MSCs' functional response towards inflammatory cues is known as MSC-"licensing" and includes indoleamine 2,3-dioxygenase (IDO) upregulation. MSCs use tryptophan-depleting IDO to suppress T-cells. Increasing evidence suggests that several functions are (co-)determined by the cells' metabolic commitment. MSCs are capable of both, high levels of glycolysis and of oxidative phosphorylation. Although several studies have addressed alterations of the immune regulatory phenotype elicited by inflammatory priming metabolic mechanisms controlling this process remain unknown. We demonstrate that inflammatory MSC-licensing causes metabolic shifts including enhanced glycolysis and increased fatty acid oxidation. Yet, only interfering with glycolysis impacts IDO upregulation and impedes T-cell-suppressivity. We identified the Janus kinase (JAK)/signal transducer and activator of transcription (STAT)1 pathway as a regulator of both glycolysis and IDO, and show that enhanced glucose turnover is linked to abundant STAT1 glycosylation. Inhibiting the responsible O-acetylglucosamine (O-GlcNAc) transferase abolishes STAT1 activity together with IDO upregulation. Our data suggest that STAT1-O-GlcNAcylation increases its stability towards degradation thus sustaining downstream effects. This pathway could represent a target for interventions aiming to enhance the MSCs' immunoregulatory potency.
引用
- Jitschin R, Böttcher M, Saul D, et al. Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylation. Leukemia. 2019. PMID: 30679801. doi:10.1038/s41375-018-0376-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。